Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
Add more filters










Database
Language
Publication year range
1.
J Cutan Pathol ; 46(2): 143-147, 2019 Feb.
Article in English | MEDLINE | ID: mdl-30362142

ABSTRACT

Cutaneous vasculitis has many underlying causes, and the clinical and histological findings often overlap. Inflammatory vasculitis can mimic infection; however, distinction is critical for the timely institution of appropriate therapy. We present two patients who had generalized polymorphous eruptions whose cutaneous pathology showed vasculitis with unusual haloed yeast-like cells within the inflammatory infiltrate, mimicking Cryptococcus. The unusual cells stained negatively with Gomori methenamine silver and periodic acid-Schiff fungal stains, but positively for CD68 and had cytoplasmic reactivity with antibody to myeloperoxidase (MPO). Both patients had positive serum anti-MPO antibodies. The first patient experienced a rapidly fatal course, whereas the second patient improved with prompt initiation of systemic corticosteroids. Interestingly, the second case had prior biopsy showing Sweet syndrome with crypotoccoid-appearing cells. Cryptococcoid cells have been described previously in association with neutrophilic dermatoses, but not in the setting of vasculitis as was seen in our patients. Our cases add to the existing literature on crypotoccoid mimickers, and are the first to be reported in association with vasculitis.


Subject(s)
Cryptococcosis , Cryptococcus , Dermatomycoses , Skin Diseases, Vascular , Sweet Syndrome , Vasculitis , Aged , Cryptococcosis/diagnosis , Cryptococcosis/metabolism , Cryptococcosis/pathology , Dermatomycoses/diagnosis , Dermatomycoses/metabolism , Dermatomycoses/pathology , Female , Humans , Skin Diseases, Vascular/diagnosis , Skin Diseases, Vascular/metabolism , Skin Diseases, Vascular/pathology , Sweet Syndrome/diagnosis , Sweet Syndrome/metabolism , Sweet Syndrome/pathology , Vasculitis/diagnosis , Vasculitis/metabolism , Vasculitis/pathology
3.
Am J Dermatopathol ; 40(12): e147, 2018 Dec.
Article in English | MEDLINE | ID: mdl-29077580
4.
J Cutan Pathol ; 44(4): 338-341, 2017 Apr.
Article in English | MEDLINE | ID: mdl-28026045

ABSTRACT

BACKGROUND: Distinguishing regressed lichen planus-like keratosis (LPLK) from regressed melanoma can be difficult on histopathologic examination, potentially resulting in mismanagement of patients. OBJECTIVE: We aimed to identify histopathologic features by which regressed melanoma can be differentiated from regressed LPLK. METHODS: Twenty actively inflamed LPLK, 12 LPLK with regression and 15 melanomas with regression were compared and evaluated by hematoxylin and eosin staining as well as Melan-A, microphthalmia transcription factor (MiTF) and cytokeratin (AE1/AE3) immunostaining. RESULTS: (1) A total of 40% of regressed melanomas showed complete or near complete loss of melanocytes within the epidermis with Melan-A and MiTF immunostaining, while 8% of regressed LPLK exhibited this finding. (2) Necrotic keratinocytes were seen in the epidermis in 33% regressed melanomas as opposed to all of the regressed LPLK. (3) A dense infiltrate of melanophages in the papillary dermis was seen in 40% of regressed melanomas, a feature not seen in regressed LPLK. CONCLUSIONS: In summary, our findings suggest that a complete or near complete loss of melanocytes within the epidermis strongly favors a regressed melanoma over a regressed LPLK. In addition, necrotic epidermal keratinocytes and the presence of a dense band-like distribution of dermal melanophages can be helpful in differentiating these lesions.


Subject(s)
Keratosis , Lichenoid Eruptions , Melanoma , Skin Neoplasms , Diagnosis, Differential , Female , Humans , Keratosis/metabolism , Keratosis/pathology , Lichenoid Eruptions/metabolism , Lichenoid Eruptions/pathology , Male , Melanoma/metabolism , Melanoma/pathology , Skin Neoplasms/metabolism , Skin Neoplasms/pathology
5.
J Am Acad Dermatol ; 74(4): 724-30.e1, 2016 Apr.
Article in English | MEDLINE | ID: mdl-26803347

ABSTRACT

BACKGROUND: Acral lentiginous melanoma has increased mortality compared with other melanoma subtypes and disproportionately affects ethnic minorities. Acral melanocytic lesions have not been well studied in diverse populations of the United States. OBJECTIVE: We sought to assess the prevalence, awareness, and dermoscopic patterns of acral melanocytic lesions in skin-of-color and non-Hispanic white patients. METHODS: We prospectively examined the palms and soles of 1052 patients presenting to dermatology clinics in New York, NY, and Miami, FL, from October 2013 to April 2015. RESULTS: Acral melanocytic lesions were observed in 36% of our cohort. Skin-of-color patients were more likely to have acral melanocytic lesions than non-Hispanic white patients (P < .01). Acral melanocytic lesions correlated with increased mole counts, particularly on non-Hispanic white patients. The majority of lesions demonstrated benign dermoscopic patterns. We observed 2 lesions with the parallel ridge pattern in our cohort, both found to be atypical nevi on biopsy specimen. Patients often lacked awareness of the presence of their lesions. LIMITATIONS: Interobserver variability in assessing dermoscopic patterns is a limitation. CONCLUSIONS: Melanocytic lesions of the palms and soles are common, particularly in a cohort of multiple ethnicities from the United States. Dermoscopy of acral lesions is an important clinical tool for diagnosis and management of these lesions.


Subject(s)
Dermoscopy/methods , Melanoma/diagnosis , Nevus, Pigmented/diagnosis , Skin Neoplasms/diagnosis , Skin Pigmentation/physiology , White People/statistics & numerical data , Aged , Aged, 80 and over , Awareness , Biopsy, Needle , Cohort Studies , Female , Florida/epidemiology , Humans , Immunohistochemistry , Male , Melanoma/ethnology , Middle Aged , Neoplasm Invasiveness/pathology , Neoplasm Staging , Nevus, Pigmented/ethnology , Observer Variation , Prevalence , Prospective Studies , Risk Assessment , Skin Neoplasms/ethnology , United States/epidemiology
6.
JAMA Dermatol ; 151(3): 285-92, 2015 Mar.
Article in English | MEDLINE | ID: mdl-25565224

ABSTRACT

IMPORTANCE: Secondary infections and impaired desquamation complicate certain inherited ichthyoses, but their cellular basis remains unknown. In healthy human epidermis, the antimicrobial peptides cathelicidin (LL-37) and human ß-defensin 2 (HBD2), as well as the desquamatory protease kallikrein-related peptidase 7 (KLK7), are delivered to the stratum corneum (SC) interstices by lamellar body (LB) exocytosis. OBJECTIVE: To assess whether abnormalities in the LB secretory system could account for increased risk of infections and impaired desquamation in inherited ichthyoses with known abnormalities in LB assembly (Harlequin ichthyosis [HI]), secretion (epidermolytic ichthyosis [EI]), or postsecretory proteolysis (Netherton syndrome [NS]). DESIGN, SETTING, AND PARTICIPANTS: Samples from library material were taken from patients with HI, EI, NS, and other ichthyoses, but with a normal LB secretory system, and in healthy controls and were evaluated by electron microscopy and immunohistochemical analysis from July 1, 2010, through March 31, 2013. MAIN OUTCOME AND MEASURES: Changes in LB secretion and in the fate of LB-derived enzymes and antimicrobial peptides in ichthyotic patients vs healthy controls. RESULTS: In healthy controls and patients with X-linked ichthyosis, neutral lipid storage disease with ichthyosis, and Gaucher disease, LB secretion is normal, and delivery of LB-derived proteins and LL-37 immunostaining persists high into the SC. In contrast, proteins loaded into nascent LBs and their delivery to the SC interstices decrease markedly in patients with HI, paralleled by reduced immunostaining for LL-37, HBD2, and KLK7 in the SC. In patients with EI, the cytoskeletal abnormality impairs the exocytosis of LB contents and thus results in decreased LL-37, HBD2, and KLK7 secretion, causing substantial entombment of these proteins within the corneocyte cytosol. Finally, in patients with NS, although abundant enzyme proteins loaded in parallel with accelerated LB production, LL-37 disappears, whereas KLK7 levels increase markedly in the SC. CONCLUSIONS AND RELEVANCE: Together, these results suggest that diverse abnormalities in the LB secretory system account for the increased risk of secondary infections and impaired desquamation in patients with HI, EI, and NS.


Subject(s)
Exocytosis , Ichthyosis/complications , Skin Diseases, Infectious/etiology , Skin/pathology , Antimicrobial Cationic Peptides/metabolism , Case-Control Studies , Humans , Ichthyosis/genetics , Ichthyosis/pathology , Immunohistochemistry , Kallikreins/metabolism , Microscopy, Electron , Skin Diseases, Infectious/pathology , beta-Defensins/metabolism , Cathelicidins
7.
Wound Repair Regen ; 21(5): 715-22, 2013.
Article in English | MEDLINE | ID: mdl-23927023

ABSTRACT

Stress slows cutaneous wound healing (WH) in an endogenous glucocorticoid (GC)-dependent fashion. We investigated whether stress/GC-induced delays in WH require further intracutaneous activation of endogenous GC; and whether blockade or down-regulation of peripheral activation normalizes WH in the face of stress. Delayed WH in our motion-restricted murine model of stress could be attributed to elevated systemic GC, because blockade of GC production (using corticotropin-releasing factor inhibitor, antalarmin), or of peripheral binding to the GC receptor [GCr], with an antagonist, Ru-486, normalized WH. We next investigated whether local blockade or down-regulation of the peripheral GC-activating enzyme, 11ß-hydroxysteroid dehydrogenase type 1 (11ß-HSD1), accelerates cutaneous WH. Topical applications of nonspecific (carbenoxolone) as well as an isoform-specific 11ß-HSD1 inhibitor overcame stress and exogenous GC-induced delays in WH. Moreover, two liver X receptor ligands, TO901317 and GW3695, down-regulated expression of 11ß-HSD1, attenuating stress-induced delays in WH. Combined inhibitor and liver X receptor ligand applications accelerated WH in the face of stress/systemic GC. Thus: (1) intracutaneous conversion of inactive-to-active GC accounts for stress (GC)-induced delays in WH; and (2) blockade or down-regulation of 11ß-HSD1 and/or GCr normalize cutaneous WH in the face of stress/GC. Local blockade or down-regulation of cutaneous GC activation could help enhance WH in various clinical settings.


Subject(s)
11-beta-Hydroxysteroid Dehydrogenase Type 1/pharmacology , Glucocorticoids/antagonists & inhibitors , Liver/metabolism , Receptors, Glucocorticoid/antagonists & inhibitors , Stress, Psychological/metabolism , Wound Healing , Animals , Blotting, Western , Cells, Cultured , Down-Regulation/drug effects , Glucocorticoids/pharmacology , Immunohistochemistry , Male , Mice , Mice, Inbred C57BL , Real-Time Polymerase Chain Reaction , Wound Healing/drug effects
8.
Mol Genet Metab ; 104(4): 631-6, 2011 Dec.
Article in English | MEDLINE | ID: mdl-21982627

ABSTRACT

BACKGROUND: Type 2 Gaucher disease is a rare and progressive subtype of this lysosomal storage disorder, marked by rapid, early-onset neurodegeneration. Distinguishing type 2 from types 1 and 3 Gaucher disease has remained challenging, due to the lack of a clear correlation between phenotype and enzymatic activity or genotype. ß-glucocerebrosidase, the enzyme deficient in Gaucher disease, also has an essential role in maintaining epidermal permeability function, by regulating the ratio of ceramides to glucosylceramides in the stratum corneum of the skin. OBJECTIVES: To further assess the diagnostic utility of epidermal evaluations in distinguishing patients with type 2 Gaucher disease in an expanded cohort. STUDY DESIGN: Epidermal samples were evaluated from twenty children with type 2, three patients with type 3 Gaucher disease and two adults with type 1 Gaucher disease with different clinical manifestations and genotypes. Electron microscopy on ruthenium tetroxide post-fixed tissue was performed. RESULTS: Compared to controls and subjects with type 1 and type 3 Gaucher disease, only patients with type 2 Gaucher disease displayed characteristic electron dense, non-lamellar clefts and immature-lamellar membranes. CONCLUSION: The appearance of characteristic alterations in epidermal ultrastructure provides an early and specific diagnostic tool to help in distinguishing type 2 from the other types of Gaucher disease.


Subject(s)
Epidermis/pathology , Gaucher Disease/diagnosis , Gaucher Disease/pathology , Adolescent , Biopsy , Child , Child, Preschool , Diagnosis, Differential , Female , Gaucher Disease/genetics , Genetic Association Studies , Humans , Infant , Male , Microscopy, Electron , Middle Aged , Mutation, Missense , Pregnancy , Prenatal Diagnosis , Prognosis , Young Adult
9.
Dermatoendocrinol ; 3(2): 84-90, 2011 Apr.
Article in English | MEDLINE | ID: mdl-21695017

ABSTRACT

The function of the epidermis is to form an effective barrier between the dry, external environment and the interior of the body. The barrier specifically resides in the extracellular lipid membranes of the stratum corneum (SC) and an acidic pH is necessary to maintain its competency against various insults. The purpose of this review is to explore the mechanisms which are postulated to contribute to the acidification of the stratum corneum, including both exogenous and endogenous sources. However, recent research as pointed to several endogenous mechanisms as the major source of acidification, including a sodium/proton pump (NHE1) and free fatty acid conversion from phospholipids by secretory phospholipase A(2) (sPLA(2)). sPLA(2) has been shown to play a central role in the formation of the SC "acid mantle" in the early maturation of the epidermis postnatally. Many aspects of this enzyme family are complex and still being elucidated in research and the most recent findings on the localization and functions of sPL A(2)-IB, -IIA, -IIC, -IID, -IIE, -IIF, -III, -V, -X and -XII in the epidermis are presented here. Given their role in inflammatory dermatoses, such as psoriasis and atopic dermatitis, understanding this complex enzyme family can lead to novel, life-changing therapies.

SELECTION OF CITATIONS
SEARCH DETAIL
...